Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2019-06-25

FDA Approved: XALKORI — Supplemental Application (Pfizer Laboratories Div Pfizer Inc)

View source ↗

Summary

FDA approves a supplemental application for XALKORI (crizotinib) filed by Pfizer Laboratories Div Pfizer Inc.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Xalkori (crizotinib)

Snippet

SUPPL AP for XALKORI (CRIZOTINIB)